Sandbox: wdx causes: Difference between revisions
Jump to navigation
Jump to search
| Line 8: | Line 8: | ||
! rowspan="5" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Condition | ! rowspan="5" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Condition | ||
! rowspan="5" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Etiology | ! rowspan="5" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Etiology | ||
! colspan=" | ! colspan="4" rowspan="3" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Mechanism | ||
! rowspan="5" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Congenital | ! rowspan="5" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Congenital | ||
! rowspan="5" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Acquried | ! rowspan="5" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Acquried | ||
! colspan="9" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Clinical manifestations | ! colspan="9" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Clinical manifestations | ||
! colspan=" | ! colspan="6" rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Para−clinical findings | ||
! colspan="1" rowspan="5" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Gold standard | ! colspan="1" rowspan="5" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Gold standard | ||
! rowspan="5" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Associated findings | ! rowspan="5" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Associated findings | ||
| Line 21: | Line 21: | ||
| colspan="4" rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Signs | | colspan="4" rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Signs | ||
|- | |- | ||
! colspan=" | ! colspan="6" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Lab Findings | ||
|- | |- | ||
! rowspan="2" |Physiologic | |||
! colspan="2" |increased bone marrow production | |||
! rowspan="2" |demargination of peripheral blood neutrophils | |||
! colspan="1" rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Appearance | ! colspan="1" rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Appearance | ||
! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Fever | ! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Fever | ||
| Line 33: | Line 36: | ||
! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |PBS | ! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |PBS | ||
! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Bone marrow exam | ! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Bone marrow exam | ||
! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" | | ! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |ESR/CRP | ||
|- | |- | ||
! | !autonomous | ||
! | !reactive | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Plt | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Plt | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |HB | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |HB | ||
| Line 48: | Line 48: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| | |||
| | |||
| | |||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| Line 75: | Line 74: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| | |||
| | |||
| | |||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| Line 102: | Line 100: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| | |||
| | |||
| | |||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| Line 129: | Line 126: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| | |||
| | |||
| | |||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| Line 156: | Line 152: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| | |||
| | |||
| | |||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| Line 183: | Line 178: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| | |||
| | |||
| | |||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| Line 207: | Line 201: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
|- | |- | ||
! rowspan=" | ! rowspan="9" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Immunology/ | ||
Rheumatology | Rheumatology | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Condition | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Condition | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Etiology | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Etiology | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Physiologic | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Physiologic | ||
! | ! | ||
! | ! | ||
! | |||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Congenital | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Congenital | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Acquried | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Acquried | ||
| Line 230: | Line 225: | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |PBS | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |PBS | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Bone marrow exam | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Bone marrow exam | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" | | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |ESR/CRP | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Gold standard | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Gold standard | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Associated findings | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Associated findings | ||
|- | |- | ||
! align="center" style="background:#DCDCDC;" | | ! align="center" style="background:#DCDCDC;" |Rheumatoid arthritis | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| | |||
| | |||
| | |||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| Line 263: | Line 255: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
|- | |- | ||
! align="center" style="background:#DCDCDC;" | | ! align="center" style="background:#DCDCDC;" |Juvenile onset rheumatoid arthritis | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| | |||
| | |||
| | |||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| Line 289: | Line 280: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
|- | |||
!adult Still's disease | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
|- | |||
!Kawasaki disease | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
|- | |- | ||
! align="center" style="background:#DCDCDC;" |IBD | ! align="center" style="background:#DCDCDC;" |IBD | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| | |||
| | |||
| | |||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| Line 320: | Line 362: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| | |||
| | |||
| | |||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| Line 339: | Line 384: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| | |- | ||
!Sweet syndrome | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
|- | |- | ||
! align="center" style="background:#DCDCDC;" |Acute Gout | ! align="center" style="background:#DCDCDC;" |Acute Gout | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| | |||
| | |||
| | |||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| Line 371: | Line 437: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
|- | |- | ||
! rowspan=" | ! rowspan="5" |Infections | ||
! align="center" style="background:#DCDCDC;" | | ! align="center" style="background:#DCDCDC;" |Acute bacterial | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| | |||
| | |||
| | |||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| Line 394: | Line 458: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + |toxic granulations, Döhle bodies, and cytoplasmic vacuoles in neutrophils | |||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| Line 399: | Line 464: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
|- | |- | ||
! align="center" style="background:#DCDCDC;" | | ! align="center" style="background:#DCDCDC;" |Chronic | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| | |||
| | |||
| | |||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| Line 426: | Line 490: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
|- | |- | ||
! | !Viral infection | ||
| | ! | ||
! | |||
| | ! | ||
| | ! | ||
! | |||
! | |||
! | |||
!Children | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
|- | |||
!granulomatous infections | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
|- | |||
!bronchiectasis | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
|- | |||
! rowspan="4" |Metabolic | |||
!Diabetic coma | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
|- | |||
!Acidosis | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
|- | |||
!Thyroid strom | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
|- | |||
!Seizures | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
|- | |- | ||
! | ! | ||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
|- | |- | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Category | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Category | ||
| Line 484: | Line 704: | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Etiology | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Etiology | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Physiologic | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Physiologic | ||
! | ! | ||
! | ! | ||
! | |||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Congenital | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Congenital | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Acquried | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Acquried | ||
| Line 502: | Line 723: | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |PBS | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |PBS | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Bone marrow exam | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Bone marrow exam | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" | | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |ESR/CRP | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Gold standard | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Gold standard | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Associated findings | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Associated findings | ||
|- | |- | ||
! rowspan="4" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Medications | ! rowspan="4" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Medications | ||
! align="center" style="background:#DCDCDC;" |Steriod | ! align="center" style="background:#DCDCDC;" |Steriod | ||
| align="center" style="background:#F5F5F5;" + |Release of granulocytes from the bone marrow | |||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| | |||
| | |||
| | |||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| Line 594: | Line 757: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| | |||
| | |||
| | |||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| Line 621: | Line 783: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| | |||
| | |||
| | |||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| Line 646: | Line 807: | ||
|- | |- | ||
! align="center" style="background:#DCDCDC;" |Cytokines | ! align="center" style="background:#DCDCDC;" |Cytokines | ||
| align="center" style="background:#F5F5F5;" + |Stimulation of bone marrow myelopoiesis and/or egress into the circulation | |||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| | |||
| | |||
| | |||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| Line 676: | Line 836: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| | |||
| | |||
| | |||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| Line 703: | Line 862: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| | |||
| | |||
| | |||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| Line 730: | Line 888: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| | |||
| | |||
| | |||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| Line 757: | Line 914: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| | |||
| | |||
| | |||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| Line 785: | Line 941: | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Etiology | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Etiology | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Physiologic | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Physiologic | ||
! | ! | ||
! | ! | ||
! | |||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Congenital | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Congenital | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Acquried | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Acquried | ||
| Line 803: | Line 960: | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |PBS | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |PBS | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Bone marrow exam | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Bone marrow exam | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" | | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |ESR/CRP | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Gold standard | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Gold standard | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Associated findings | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Associated findings | ||
|} | |} | ||
<references /> | <references /> | ||
Revision as of 18:00, 13 September 2018
Differentiating Leukocytosis from Other Diseases
- Leukocytosis is defined as an elevated white blood cell (WBC) count greater than 11,000 per mm3 (11.0 × 109 per L).
- The most common type of leukocytosis is neutrophilia.
- Neutrophilia can be defined as an increase in the absolute number of mature neutrophils to greater than 7,000 per mm3 [7.0 × 109 per L].
| Category | Condition | Etiology | Mechanism | Congenital | Acquried | Clinical manifestations | Para−clinical findings | Gold standard | Associated findings | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Demography | History | Symptoms | Signs | ||||||||||||||||||||||
| Lab Findings | |||||||||||||||||||||||||
| Physiologic | increased bone marrow production | demargination of peripheral blood neutrophils | Appearance | Fever | Bleeding | BP | Splenomegaly | Jaundice | Other | CBC | PBS | Bone marrow exam | ESR/CRP | ||||||||||||
| autonomous | reactive | Plt | HB | WBC | |||||||||||||||||||||
| Hematologic | Hereditary neutrophilia | ||||||||||||||||||||||||
| Chronic idiopathic neutrophilia | |||||||||||||||||||||||||
| CML | |||||||||||||||||||||||||
| Polycythemia Vera | |||||||||||||||||||||||||
| Hemolytic anemia | |||||||||||||||||||||||||
| Immature thrombocytopenia | |||||||||||||||||||||||||
| Immunology/
Rheumatology |
Condition | Etiology | Physiologic | Congenital | Acquried | Demography | History | Appearance | Fever | Bleeding | BP | Splenomegaly | Jaundice | Other signs | Plt | HB | WBC | PBS | Bone marrow exam | ESR/CRP | Gold standard | Associated findings | |||
| Rheumatoid arthritis | |||||||||||||||||||||||||
| Juvenile onset rheumatoid arthritis | |||||||||||||||||||||||||
| adult Still's disease | |||||||||||||||||||||||||
| Kawasaki disease | |||||||||||||||||||||||||
| IBD | |||||||||||||||||||||||||
| Chronic hepatitis | |||||||||||||||||||||||||
| Sweet syndrome | |||||||||||||||||||||||||
| Acute Gout | |||||||||||||||||||||||||
| Infections | Acute bacterial | toxic granulations, Döhle bodies, and cytoplasmic vacuoles in neutrophils | |||||||||||||||||||||||
| Chronic | |||||||||||||||||||||||||
| Viral infection | Children | ||||||||||||||||||||||||
| granulomatous infections | |||||||||||||||||||||||||
| bronchiectasis | |||||||||||||||||||||||||
| Metabolic | Diabetic coma | ||||||||||||||||||||||||
| Acidosis | |||||||||||||||||||||||||
| Thyroid strom | |||||||||||||||||||||||||
| Seizures | |||||||||||||||||||||||||
| Category | Condition | Etiology | Physiologic | Congenital | Acquried | Demography | History | Appearance | Fever | Bleeding | BP | Splenomegaly | Jaundice | Other signs | Plt | HB | WBC | PBS | Bone marrow exam | ESR/CRP | Gold standard | Associated findings | |||
| Medications | Steriod | Release of granulocytes from the bone marrow | |||||||||||||||||||||||
| Lithium | |||||||||||||||||||||||||
| Beta agonists | |||||||||||||||||||||||||
| Cytokines | Stimulation of bone marrow myelopoiesis and/or egress into the circulation | ||||||||||||||||||||||||
| Other | Post splenectomy | ||||||||||||||||||||||||
| Down syndrome | |||||||||||||||||||||||||
| Birth | |||||||||||||||||||||||||
| Pregnancy | |||||||||||||||||||||||||
| Category | Condition | Etiology | Physiologic | Congenital | Acquried | Demography | History | Appearance | Fever | Bleeding | BP | Splenomegaly | Jaundice | Other signs | Plt | HB | WBC | PBS | Bone marrow exam | ESR/CRP | Gold standard | Associated findings | |||